Can preoperative neutrophil to lymphocyte and platelet to lymphocyte ratios predict cervical stromal involvemen in endometrioid endometrial adenocarcinoma?

Purpose: To evaluate the possible relationships between preoperative inflammatory markers [neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR)] and cervical stromal involvement in endometrioid endometrial adenocarcinoma. Materials and Methods: Charts and pathology results of 639 women who were operated on for endometrioid endometrial adenocarcinoma between 2000 and 2013 in the present clinic were retrospectively reviewed. Demographic, laboratory, and clinical parameters were evaluated. Results: 118 women (18.4%) had cervical stromal involvement. Lymph node positivity was significantly more frequent in the cervical stromal involvement group (p < 0.001). A threshold value of 2.41 for NLR had a sensitivity of 62.7%, specificity of 60.1%, PPV of 61.1%, and NPV of 61.8% for the presence of cervical stromal involvement. In multivariate analysis, increased NLR had a significant predictive value for cervical stromal involvement (p = 0.006, OR = 2.03), although PLR remained non-significant (p = 0.77, OR = 1.08). Conclusions: The preoperative NLR assessment is a significant predictor for cervical stromal involvement in endometrioid endometrial adenocarcinoma.

Neutrophil to lymphocyte ratio; Platelet to lymphocyte ratio; Cervical stromal involvement; Endometrioid adenocarcinoma.

[1] Berman M.L., Ballan S.C., La Gasse L.K., Watring W.G.: “'Prognosis and treatment of endometrial cancer”. Am. J. Obstet. Gynecol., 1980, 136, 679.

[2] Shephert J.H.: “Revised FIGO staging for gynaecological cancer”. Br. J. Obstet. Gynaecol., 1989, 96, 889.

[3] Nozoe T., Matsumata T., Sugimachi K.: “Preoperative elevation of serum C reactive protein is related to impaired immunity in patients with colorectal cancer”. Am. J. Clin. Oncol., 2000, 23, 263.

[4] Roxburgh C.S., McMillan D.C.: “Role of systemic inflammatory response in predicting survival in patients with primary operable cancer”. Future Oncol., 2010, 6, 149.

[5] Lord B.I., Bronchud M.H., Owens S., Chang J., Howell A., Souza L., et al.: “The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo”. Proc. Natl. Acad. Sci. USA, 1989, 86, 9499.

[6] Ulich T.R., del Castillo J., Watson L.R., Yin S.M., Garnick M.B.: “In vivo hematologic effects of recombinant human macrophage colonystimulating factor”. Blood, 1990, 75, 846.

[7] Ulich T.R., del Castillo J., Keys M., Granger G.A., Ni R.X.: “Kinetics and mechanisms of recombinant human interleukin 1 and tumor necrosis factor-alpha induced changes in circulating numbers of neutrophils and lymphocytes”. J. Immunol., 1987, 139, 3406.

[8] Walsh S.R., Cook E.J., Goulder F., Justin T.A., Keeling N.J.: “Neutrophil- lymphocyte ratio as a prognostic factor in colorectal cancer”. J. Surg. Oncol., 2005, 91, 181.

[9] Smith R.A., Bosonnet L., Raraty M., Sutton R., Neoptolemos J.P., Campbell F., et al.: “Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma”. Am. J. Surg., 2009, 197, 466.

[10] Leminen A., Forss M., Lehtovirta P.: “Endometrial adenocarcinoma with clinical evidence of cervical involvement: accuracy of diagnostic procedures, clinical course and prognostic factors”. Acta Obstet. Gynecol. Scand., 1995, 74, 61.

[11] Morrow C.P., Bundy B.N., Kurman R.J., Creasman W.T., Heller P., Homesley H.D., et al.: “Relationship between surgical–pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: Gynecologic Oncology Group Study”. Gynecol. Oncol., 1991, 40, 55.

[12] Morrow C.P., Di Saia P.J., Townsend D.E.: “Current management of endometrial carcinoma”. Obstet. Gynecol., 1973, 42, 399.

[13] Tavares-Murta B.M., Mendonça M.A., Duarte N.L., da Silva J.A., Mutão T.S., Garcia C.B., et al.: “Systemic leukocyte alterations are associated with invasive uterine cervical cancer”. Int. J. Gynecol. Cancer, 2010, 20, 1154.

[14] Feng J., Huang Y., Zhao Q., Chen Q.: “Clinical significance of preoperative neutrophil lymhocyte ratio versus platelet lymphocyte ratio in patients with small cell carcinoma of the esophagus”. Scientific- WorldJournal, 2013, 2013, 504365.

[15] Lee S., Oh S., Kim S., Lee J., Kim M., Kim K., Kim H.: “Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy”. BMC Cancer, 2013, 13, 350.

[16] Bhatti I., Peacock O., Lloyd G., Larvin M., Hall R.I.: “Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio”. Am. J. Surg., 2010, 200, 197.

[17] Eaden J., Abrams K., Ekbom A., Jackson E., Mayberry J.: “Colorectal cancer prevention in ulcerative colitis: a case-control study”. Aliment. Pharmacol. Ther., 2000, 14, 145.

[18] Matsuzaki K., Murata M., Yoshida K., Sekimoto G., Uemura Y., Sakaida N., et al.: “Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma”. Hepatology, 2007, 46, 48.

[19] van der Woude C.J., Kleibeuker J.H., Jansen P.L., Moshage H.: “Chronic inflammation, apoptosis and (pre) malignant lesions in the gastro-intestinal tract”. Apoptosis, 2004, 9, 123.

[20] Hussain S.P., Amstad P., Raja K., Ambs S., Nagashima M., Bennett W.P., et al.: “Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease”. Cancer Res., 2000, 60, 3333.

[21] Dossus L., Rinaldi S., Becker S., Lukanova A., Tjonneland A., Olsen A., et al.: “Obesity, inflammatory markers, and endometrial cancer risk: a prospective case-control study”. Endocr. Relat. Cancer, 2010, 17, 1007.

[22] Suh D.H., Kim H.S., Chung H.H., Kim J.W., Park N.H., Song Y.S., et al.: “Pre-operative systemic inflammatory response markers in predicting lymph node metastasis in endometrioid endometrial adenocarcinoma”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2012, 162, 206.

[23] Wang D., Yang J.X., Cao D.Y., Wan X.R., Feng F.Z., Huang H.F., et al.: “Preoperative neutrophil-lymphocyte and platelet-lymphocyte ratios as independent predictors of cervical stromal involvement in surgically treated endometrioid adenocarcinoma”. Onco. Targets Ther., 2013, 6, 211.